WO2004027066A2 - Protéine recombinante chimérique et diagnostic in vitro du hiv - Google Patents
Protéine recombinante chimérique et diagnostic in vitro du hiv Download PDFInfo
- Publication number
- WO2004027066A2 WO2004027066A2 PCT/FR2003/002712 FR0302712W WO2004027066A2 WO 2004027066 A2 WO2004027066 A2 WO 2004027066A2 FR 0302712 W FR0302712 W FR 0302712W WO 2004027066 A2 WO2004027066 A2 WO 2004027066A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- hiv
- region
- recombinant protein
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a chimeric recombinant protein, a DNA encoding said chimeric recombinant protein, as well as the use of this chimeric recombinant protein for the in vitro diagnosis of diseases related to a virus, more particularly the HIV-1 virus and / or and HIV-2.
- HIV-1 human immunodeficiency virus- 1
- HF / -2 human immunodeficiency virus-2
- the primary infection is followed by '' an asymptomatic period, of variable duration before the disease progresses in most AIDS patients, characterized by the appearance of opportunistic germ infections, tumors and neurological manifestations, and the early diagnosis of presence of the HIV virus in the body should be carried out whether the patient was initially infected with HIV-1 or ⁇ ar H ⁇ V-2.
- Most of the diagnostic tests marketed are based on an antigen-antibody reaction directed against certain viral proteins, such as the transmembrane proteins of the viral envelope.
- the envelope proteins are derived from the env gene, which encodes a precursor glycoprotein with a molecular weight of 160,000 daltons, called gp 160.
- the gp 160 is then cleaved into two viral proteins of the envelope, gp 120 and gp 41.
- the precursor glycoprotein is gpl40, cleaved into gp36 and gpl05 / l 10.
- patent EP-B-0 577 894 describes the construction of a chimeric recombinant protein used for the diagnosis of AIDS.
- This protein carries epitopes directed against the viral proteins derived from the HIV-2 gag gene and against the HIV-1 gpl20 protein.
- this recombinant protein does not allow the simultaneous detection of patients infected with group M and O HIV-1 viruses, which can induce risks of false negatives (patient detected seronegative while carrying the virus), false negatives whose consequences can be dramatic.
- this recombinant protein does not carry the epitope directed against gp41, which is nevertheless the major immunodominant epitope, which increases, again, the risk of appearance of false negative.
- Patent application DE 101 06 295 describes a recombinant protein comprising several epitopes directed against HIV-1 or HIV-2, linked by binding regions, making it possible to immobilize the recombinant protein on a solid support.
- epitopic regions of this recombinant protein allow the recognition of antibodies directed against the products of the pol gene of the HIV virus (protease, reverse transcriptase or endonuclease) or against the sequence which constitutes the V3 loop of gpl20. Since the proteins encoded by the pol gene are relatively conserved from one virus to another, the antibodies directed against these proteins are not very specific. In addition, the antibodies directed against the pol antigens of a virus appear in people infected late, which does not allow a diagnosis of the disease at the start of infection. It has also been shown that the titer of anti-pol antigens decreases with the progression of the disease, and that consequently, a false negative diagnosis could be attributed to a patient in the chronic infection phase.
- sequence of the V3 loop of gpl20 this sequence is hypervariable and the use of 2 or 3 sequences known as specific types does not guarantee the detection of all the antibodies directed against this domain: false negative results can therefore be obtained.
- the present invention proposes to solve all the drawbacks of the state of the art, by proposing a new chimeric recombinant protein, easy to purify and to synthesize, having a strong immunoreactivity with respect to will of patients susceptible to '' be infected with one or more viruses, such as HIV-1, group M and or O or HIV-2.
- viruses such as HIV-1, group M and or O or HIV-2.
- recombinant DNA an artificially constructed nucleotide sequence obtained by genetic engineering.
- said recombinant DNA can be inserted into an expression host organism, such as in particular a bacterium, by an expression vector, in particular a bacterial plasmid or a bacteriophage.
- nucleotide fragment a succession of at least three nucleotide acids encoding at least one amino acid is understood.
- cleavage site means a site allowing the separation of two nucleotide fragments by the action of at least one cleavage means, such as in particular a restriction enzyme which is capable, at the cleavage site level corresponding to a specific nucleotide sequence to generate for each strand two ends, one having a 3'-OH group, the other a 5'-P group.
- cleavage means such as in particular a restriction enzyme which is capable, at the cleavage site level corresponding to a specific nucleotide sequence to generate for each strand two ends, one having a 3'-OH group, the other a 5'-P group.
- chimeric recombinant protein an artificially constructed protein obtained by genetic engineering.
- said chimeric recombinant protein can be produced by a genetically modified expression host organism by insertion of the nucleotide sequence encoding said chimeric recombinant protein by an expression vector.
- epitopic region is meant a peptide region which will interact in a stereospecific manner with the paratopic peptide region of the antibody directed against the microorganism, such as in particular the virus, present in the patient's serum.
- the most immunogenic epitopic regions are said to be immunodominant.
- binding region is meant a region ensuring better accessibility of the paratopic regions of the various antibodies present in the serum of the patients with respect to the epitopic regions of interest of the chimeric recombinant protein.
- binding region is meant a region making it possible to fix said chimeric recombinant protein vis-à-vis:
- the support can be composed of materials, such as:
- metals chelate metal column for affinity chromatography
- the support can then be used as an analysis support, in particular during an ELISA (Enzym Linked ImmunoSorbent Assay), for purification steps during affinity chromatography, for washing steps when said chimeric recombinant protein, fixed on a magnetic particle is retained by magnetization in a predetermined place.
- detection molecule is meant a molecule associated with a marker making it possible to directly or indirectly generate a detectable signal. These markers can be in particular radioactive, enzymatic, fluorescent.
- the binding of the chimeric recombinant protein to said support or said detection molecule may involve ligands capable of reacting with an anti-ligand.
- ligands capable of reacting with an anti-ligand.
- the following ligand / anti-ligand pairs may be cited as examples:
- the invention relates to a recombinant DNA coding for a chimeric recombinant protein comprising ⁇ at least two first nucleotide fragments each coding for an epitopic region of the HIV-1 virus of group M or of group O or of the HIV-2 virus ⁇ at least a second nucleotide fragment coding for a binding region, ⁇ at least a third nucleotide fragment coding for a binding region characterized in that each first nucleotide fragment codes for at least one immunodominant region of the HIV-1 gp 120 glycoprotein, of the gp 41 glycoprotein group M HIV-1, group O HIV-1 gp 41 glycoprotein or group HIV-2 gp 36 glycoprotein.
- variable regions of these immunodominant region such as in particular the V3 loop of gpl20 are in no way envisaged in the present invention.
- said first nucleotide fragment has for sequence any one of the sequences SEQ ID No. 3, SEQ ID No.
- said second nucleotide fragment comprises at least one cleavage site.
- said second nucleotide fragment has for sequence at least any one of following sequences, taken alone or in combination, SEQ ID N ° 11 SEQ ID N ° 13, SEQ ID N ° 15, SEQ ID N ° 17, SEQ ID N ° 19, or SEQ ID N ° 20, SEQ ID N ° 33 , SEQ ID N ° 35, SEQ ID N ° 37, SEQ ID N ° 39, SEQ ID N ° 41, SEQ ID N ° 43 SEQ ID N ° 45, or SEQ ID N ° 47
- said third nucleotide fragment encoding a binding region is included in said second nucleotide fragment encoding a binding region.
- said third nucleotide fragment has for sequence any one of the sequences SEQ ID No 21, SEQ ID No 23 23, or SEQ ID No 25, SEQ ID No 33 , SEQ ID N ° 35, SEQ ID N ° 37 or SEQ ID N ° 39.
- nucleotide sequences according to the invention can be prepared by chemical synthesis and genetic engineering using techniques well known to those skilled in the art and described for example in Sambrook J. et al., Molecular Cloning: A Laboratory Manual, 1989.
- nucleotide sequences of the invention can be inserted into expression vectors in order to prepare the recombinant proteins of the invention.
- the invention also relates to a chimeric recombinant protein encoded by a recombinant DNA, as defined above, comprising ⁇ at least two epitopic regions of the group M or group O HIV-1 virus or the HIV-2 virus of at least one. microorganism, ⁇ at least one binding region ⁇ at least one attachment region.
- said binding region is a peptide comprising at least one glycine and / or at least one serine.
- said binding region has as sequence any one of the sequences SEQ ID No 12, SEQ ID No 14, SEQ ID No 16 or SEQ ID No 18, 34 , 36, 38, 40, 42, 44, 46, 48.
- said attachment region is a region rich in histidines and its derivatives, such as a region containing a density histidines, greater than or equal to 25%, and preferably greater than or equal to 33%.
- said attachment region is a peptide comprising at least one lysine.
- said attachment region has the sequence SEQ ID No. 22, 24 or, 26, 34, 36, 38 or 40.
- the recombinant proteins of the invention can be obtained by the technique of genetic engineering which comprises the steps of:
- the invention also relates to an expression vector comprising a recombinant DNA as defined above.
- expression vector there may be mentioned, for example, plasmids, viral vectors of the vaccinia virus, adenovirus, baculovirus, bacterial vectors of the salmonella, BCG type.
- the term “means necessary for the expression of a protein” means any means which makes it possible to obtain said protein, such as in particular a promoter, a transcription terminator, an origin of replication and preferably a selection marker.
- the vectors of the invention may also include sequences necessary for targeting proteins to particular cell compartments.
- An example of targeting may be targeting to the endoplasmic reticulum obtained using addressing sequences of the type of the leader sequence derived from the E3 protein of the adenovirus (Ciernik IF, et al., The Journal of Immunology, 1999, 162, 3915-3925).
- yeasts such as those of the following families: Saccharomyces,
- eukaryotic cells examples include cells from animals such as mammals, reptiles, insects and the like.
- Preferred eukaryotic cells are cells from the Chinese hamster (CHO cells), monkey (COS and Vero cells), dwarf hamster kidney (BHK cells), pig kidney (PK 15 cells) and rabbit kidney ( RK13 cells, human osteosacorm cell lines (cells 143 B), human HeLa cell lines and human hepatoma cell lines (such as Hep G2 cells), as well as insect cell lines (e.g. of Spodopterafrugiperda).
- the invention relates to the use of at least one DNA as defined above and / or at least one chimeric recombinant protein as defined above for in vitro diagnosis. This use allows the detection of the HIV-1 group M and O virus as well as the detection of the HIV-2 virus.
- Example 1 Construction of the recombinant chimeric proteins b-HIV72, b-HIV86 and b-HIV98 allowing the recognition of anti-HIV-1 group O and M and HIV-2 antibodies.
- the nucleotide sequence SEQ JJD No. 1 was designed to code for a recombinant protein b-HIV72, and cloned into an expression vector. It corresponds to the following sequence:
- the chimeric recombinant protein b-HIV72 coded by the sequence SEQ ID No. 1, comprises 137 amino acids, for a molecular mass of 15,191.5 Da. Its amino acid sequence is as follows:
- This b-HIV72 chimeric recombinant protein comprises: a) several epitopic regions (indicated in bold in SEQ ID No. 2) allowing:
- sequence SEQ ID No. 3 is derived from the viral strain HIV-1 group M (reference clone HXB2) and corresponds to the following sequence:
- This sequence is amplified by PCR (polymerase chain reaction) by the use of specific amplification primers (primer 5 ′ AGT CGG ATC CAG AAT
- the nucleotide fragment obtained codes for the peptide corresponding to the amino acid sequence SEQ ID No. 4: RILAVERYLK DQQLLGIWGC SGKLICTTAV. • recognition of anti-HIV-1 antibodies (group O; gp41):
- sequence SEQ JD No. 5 corresponds to an artificial DNA sequence, designed from the amino acid sequence of the viral strain HIV-1 group O [clone ANT70]. This synthetic portion was designed by selecting codons whose use is favorable for gene expression in E. coli.
- the sequence is as follows: SEQ ID N ° 5: CGT CTG CTT GCT CTG GAA ACC CTG CTT CAG AAC CAA CAG CTG CTT TCT CTG TGG GGT TGC AAA GGT AAG CTG GTT TGC TAC ACCTCT GTT.
- This sequence is constructed by PCR by the use of 3 oligonucleotides (a 5 'sense oligonucleotide AAG TCT GCA GGC CGT CTG CTT GCT CTG GAA ACC CTG CTT CAG AAC CAA CAG CTG CTT TCT 3' and two 5 'antisense oligonucleotides GCT ATC TAG ATC AAT GGT GAT GGT GAT GGT GGG AAG CTT TAA CAG AGG TGT AGC AAA C 3 'and 5' AAC AGA GGT GTA GCA AAC CAG CTT ACC TTT GCA ACC CCA CAG AGA AAG CAG CTG TTG GTT 3 '; 17 PCR cycles are performed with each cycle a denaturation step at 9 ° C for 1 min, a hybridization step at 50 ° C for 1 min and an elongation step 68 ° C for 20 seconds).
- This nucleotide fragment codes for the peptide corresponding to the amino
- SEQ ID No. 7 is derived from the viral strain HIV-2 (reference clone ROD) and corresponds to the following sequence: SEQ ID No. 7: GCT ATA GAG AAG TAC CTA CAG GAC CAG GCG CGG CTA AATTCATGG GGATGTGCGTTTAGACAAGTC TGC
- This sequence is amplified by PCR by the use of specific amplification primers (5 'sensible primer CTG TGA GCT CCG GTT CAG GCG CTA TAG AGA AGT ACC TA 3' and 5 'antisense primer AGA ACC GCT CGA GCA GAC TTG TCT AAA CGC 3 '; 17 PCR cycles are performed with each cycle a denaturation step at 94 ° C for 1 min, a hybridization step at 52 ° C for 1 min and an elongation step 72 ° C for 20 seconds).
- This nucleotide fragment codes for the peptide corresponding to the amino acid sequence SEQ ID No. 8: AIEKYLQDQA RLNSWGCAFR QVC. • recognition of anti-HIV-1 antibodies (group M; gp ⁇ O):
- sequence SEQ ID No. 9 is derived from the viral strain HIV-1 group M (reference clone HXB2) and corresponds to the following sequence:
- This sequence is amplified by PCR by the use of specific amplification primers (5 'sensible primer GTC TGC TCG AGC GGT TCT GGA GGA GGA GAT ATG AGG 3' and 5 'antisense primer ACG TCC TGC AGA CTT GGT GGG TGC TAC 3 'TCC; 17 cycles of PCR are carried out comprising at each cycle a denaturation step at 94 ° C for 1 min, a hybridization step at 52 ° C for 1 min and an elongation step at 72 ° C for 20 seconds ).
- This nucleotide fragment codes for the peptide corresponding to the amino acid sequence SEQ ID No. 10: GGGDMRDNWR SELYKYKWK IEPLGVAPTK
- restriction enzymes which can be used to modify, remove or add an epitopic domain
- nucleotide sequence SEQ ID No. 1 1 G AGC TCC GGT TCA GGC allows a cleavage site to be obtained by the enzyme Sac I (indicated in bold), the G indicated in italics, being the last base.
- Sac I indicated in bold
- the nucleotide sequence coding for the peptide allowing the recognition of anti-HIV-1 antibodies, group M.
- This sequence codes for the flexible region corresponding to the peptide of sequence SEQ ID No. 12: SSG SG.
- the nucleotide sequence SEQ ID N ° 13: CTCG AGC GGT TCT allows a cleavage site to be obtained by the enzyme Xho I (indicated in bold), the C indicated in italics, being the last base of the nucleotide sequence coding the peptide allowing the recognition of anti-HIV-2 antibodies.
- This sequence codes for the flexible region corresponding to the peptide of sequence SEQ ID No. 14: SSGS.
- this particular attachment region comprising a succession of histidine, allows in particular the oriented attachment of the recombinant protein on a support consisting of silica or metal oxides, as described in patent FR-B- 98 / 04,879.
- the order of the sequences coding the different immunodominant epitopic regions of the chimeric recombinant protein can possibly be modified. Certain epitopes can be presented several times within the chimeric recombinant protein. The epitopes can also present variations compared to the sequences described in the example above according to the subtype or the HIV clone that they represent. The length of the binding regions can also be varied to improve the accessibility of an epitope. Finally, the attachment regions can be inserted within the link regions.
- sequence SEQ ID No. 27 is derived from the viral strain HIV-1 group M (reference clone HXB2) and corresponds to the following sequence:
- SEQ ID N ° 27 GAA AGA TAC CTA AAG GAT CAA CAG CTC CTA GGG ATT
- This nucleotide fragment codes for the peptide corresponding to the amino acid sequence SEQ JX) No. 28: ERYLKDQQLL GIWGCSGKLI CTT.
- the sequence SEQ ID No. 29 corresponds to an artificial DNA sequence, designed from the amino acid sequence of the viral strain HIV-1 group O [clone ANT70].
- This synthetic portion was designed by selecting codons whose use is favorable for gene expression in E. coli.
- the sequence is as follows: SEQ ID N ° 29: GAA ACC CTG CTT CAG AAC CAA CAG CTG CTT TCT CTG
- This nucleotide fragment codes for the peptide corresponding to the amino acid sequence SEQ ID No. 30: ETLLQNQQLL SLWGCKGKLV CYT. • recognition of anti-H ⁇ V-2 antibodies (gp36):
- the sequence SEQ ID No. 31 is derived from the viral strain HIV-2 (reference clone
- This nucleotide fragment codes for the peptide corresponding to the amino acid sequence SEQ ID No. 32: LNSWGCAFR QVC
- nucleotide sequence SEQ ID No. 49 was designed to encode a recombinant protein according to the invention, and cloned in an expression vector.
- the chimeric recombinant protein coded by the sequence SEQ JO No. 50 is as follows:
- the epitopic regions are indicated in bold, the binding region in italics and the binding regions in non-bold non-italics.
- nucleotide sequence SEQ ID No. 51 was designed to encode a recombinant protein according to the invention, and cloned in an expression vector.
- the epitopic regions are indicated in bold, the binding region in italics and the binding regions in non-bold non-italics.
- Example 2 Expression and purification of the chimeric recombinant proteins b-HIV 72, b-HIV86 and b-HIV98 of Example 1
- the first step consists in inserting the sequence SEQ ID No. 1 (example 1), into an expression vector (pMR) then transforming an E. coli bacterium (strain BL21) with the plasmid construction obtained according to a conventional cloning protocol. known to those skilled in the art.
- the transformed bacteria are selected thanks to their resistance to ampicillin carried by the vector pMR.
- a clone of recombinant bacteria is then selected to seed a preculture of 40 ml of 2x YT medium (tryptone 16 g / 1; yeast extract 10 g / 1; NaCl 5 g / 1, pH 7.0) containing 100 ⁇ g / ml ampicillin .
- 2x YT medium tryptone 16 g / 1; yeast extract 10 g / 1; NaCl 5 g / 1, pH 7.0
- this preculture is used to inoculate 1 liter of 2xYT medium containing 2% glucose and 100 ⁇ g / ml ampicillin. This culture is incubated at 37 ° C with shaking at 250 rpm.
- IPTG isopropyl- ⁇ -D-thiogalactoside, Eurogentec
- IPTG isopropyl- ⁇ -D-thiogalactoside, Eurogentec
- the culture is centrifuged at 6000 rpm for 30 min at 4 ° C and the pellet of bacteria is frozen at - 80 ° C.
- the thawed bacteria are lysed.
- the bacteria pellets corresponding to a culture of one liter are taken up in 100 ml of lysis buffer (PBS IX containing protease inhibitors: lysozyme: 1 mg / ml; benzonase: 2.5 units per ml (Novagen ®) and Mg: 1 mM) by vortexing until a homogeneous suspension is obtained.
- lysis buffer PBS IX containing protease inhibitors: lysozyme: 1 mg / ml; benzonase: 2.5 units per ml (Novagen ®) and Mg: 1 mM
- This solution is incubated for 1 hour at room temperature with shaking.
- the solution is then centrifuged 30 min at 4 ° C at 10,000 g.
- the pellet obtained contains the inclusion bodies.
- This pellet is suspended in 50 ml of solubilization buffer (sodium bicarbonate: 40 mM; NaCl: 300 mM; SDS: 1%; ⁇ -mercaptoethanol: 20 mM, pH 9.6) containing protease inhibitors (complete EDTA-free, Roche®).
- solubilization buffer sodium bicarbonate: 40 mM; NaCl: 300 mM; SDS: 1%; ⁇ -mercaptoethanol: 20 mM, pH 9.6
- the solution thus obtained is incubated for 16 to 18 h with shaking between 18 and 25 ° C. It is then diluted to a quarter with a 2X PBS buffer containing 8 mM imidazole and protease inhibitors (complete EDTA-free, Roche®) at pH 8.0.
- the elution of the recombinant protein is obtained by application of a buffer B1 (PBS 2X, 4M urea, 100 mM imidazole, pH 7.5 , containing 5 mM ⁇ -mercaptoethanol) or B2 (PBS 2X, 0.25% SDS, 100 mM imidazole, pH 7.5, containing 5 mM ⁇ -mercaptoethanol).
- B1 PBS 2X, 4M urea, 100 mM imidazole, pH 7.5 , containing 5 mM ⁇ -mercaptoethanol
- B2 PBS 2X, 0.25% SDS, 100 mM imidazole, pH 7.5, containing 5 mM ⁇ -mercaptoethanol
- Quantities of the order of 50 mg of purified recombinant protein can be obtained from a liter of culture.
- the recombinant protein thus purified is subjected to a denaturing treatment by addition of SDS (1500 molecules per molecule of recombinant protein), DIT 5 mM, 50 mM sodium bicarbonate at pH 9.6 and heating 30 min at 37 ° C.
- SDS 1500 molecules per molecule of recombinant protein
- DIT 5 mM 50 mM sodium bicarbonate at pH 9.6
- the stocking of SDS molecules / recombinant protein molecules can be modified (ideally reduced if the heating time or temperature is increased). For example, similar results are obtained by adding 250 molecules of SDS / molecule of recombinant protein, 5 mM DTT, 50 mM sodium bicarbonate at pH 9.6 and heating for 2 hours at 40 ° C.
- the protein thus denatured is stabilized by addition of Polyethylene glycol (MW 3350 in particular) for a stockiometry of 10 PEG molecules per protein molecule then dialyzed at 4 ° C for 18 to 24 hours against a 50mM sodium bicarbonate buffer, EDTA ImM , SDS 0.01%, PEG 1 mg / 1, pH 9.6.
- the expression and the purification of the chimeric recombinant proteins b-HIV86 and b-HIV98 were carried out in a comparable manner, with the exception of the denaturation step by SDS and DTT, which is not necessary during the purification of the proteins b-HIV86 and b-HIV98.
- the use of beta mercaptoethanol in purification buffers is also not necessary.
- Example 3 Evaluation and validation of the chimeric recombinant protein b-HTV 72, bHIV 86 and b-HIV98 in a VIDAS® test (bioMérieux)
- VIDAS® test The principle of the VIDAS® test is as follows: a cone constitutes the solid support which also serves as a pipetting system for the reagents present in the strip. The recombinant protein is attached to the cone. After a dilution step, the sample is aspirated and discharged several times inside the cone. This allows the anti-HIV IgGs in the sample to bind to the recombinant protein. Unbound components are washed away. An anti-human IgG antibody conjugated with alkaline phosphatase (PAL) is then incubated in the cone where it binds to anti-HIV IgG. Washing steps remove the unbound conjugate.
- PAL alkaline phosphatase
- the PAL substrate 4-methyl-umbelliferyl phosphate
- 4-methyl-ombelliferone the fluorescence of which is emitted at 450 nm is measured.
- the intensity of the fluorescence is measured by the Vidas® optical system and is proportional to the presence of anti-HIV IgG present in the sample.
- the results are automatically analyzed by VIDAS® and expressed in RFV (Relative Fluorescent Value).
- a recombinant protein solution obtained according to Examples 1 and 2 (1.2 ⁇ g in one milliliter of 50 mM sodium bicarbonate buffer, SDS 0.01%, pH 9.6-9.8) is incubated with VIDAS® 18 cones for 24 h at room temperature (120 ⁇ l / cone).
- the cones are then incubated in a passivation buffer (330 ⁇ l / cone of HIV Duo buffer containing 3% calf serum) for 18 to 24 h at room temperature Test solutions (Etableau für du Sang, France), of HIV serology known, (28 ⁇ l of serum, of known HIV status, diluted in 300 ⁇ l of PBS 1 X buffer, NaCl 8.76 g / 1, tween 20 2.5% (v / v), skimmed milk powder 2.5 g / 1, albumin 20 g / 1, and 3% (v / v) calf serum, pH 6.1) are then brought into contact with the cones having the recombinant proteins of Example 1, for 13 min and 20 seconds (80 pipetting / delivery cycles of 10 seconds).
- a passivation buffer 330 ⁇ l / cone of HIV Duo buffer containing 3% calf serum
- a washing step is then carried out in Tris buffer 24.23 g / 1, maleic acid 23.22 g / 1, tween 20 0.05% (v / v), NaOH 6 g / 1, NaCl 8.77 g / 1, pH 6.1.
- a solution of anti-human Fc antibodies conjugated to PAL (P5F2F7) and diluted to l / 5000 emc is incubated in contact with the cone for 5 min (with 30 pipetting / delivery cycles of 10 seconds each).
- a final washing step is carried out in HIV Duo buffer, before the final revelation step.
- RFV Relative Fluorescent Value
- Example 4 Construction of a Recombinant Biotinylated Protein
- a consensus sequence of in vivo biotinylation in E.coli as described by Schatz, (Bio / technology, vol. 11, 1993) can be merged with SEQ ID No. 2 L ' addition of the sequence SEQ ID N ° 23: 5 'CTG CAC CAT ATC CTG GAA GCC CAG AAA ATG GAA TGG CAC CCG CAC, coding the peptide with sequence SEQ ID N ° 24: LHHILEAQKM EWHPH, allows the biotinylation of the recombinant protein b HIV72 obtained according to Examples 1 and 2 in order to use an avidin protein conjugated to an enzyme for the development phase in an EIA test.
- the bacteria transformed with the recombinant plasmid can be of the BL21 or AVB101 type (Avidity, LLC).
- the culture medium used for the expression can be of the type: 2x YT (tryptone 16 g / 1; yeast extract 10 g / 1; NaCl 5 g / 1, pH 7.0) containing 100 ⁇ g / ml ampicillin and supplemented with 12 ⁇ g per ml of biotin.
- Example 5 Evaluation and validation of the chimeric recombinant protein biotinylated in vivo as described in Example 4 in a VIDAS® test of the sandwich type.
- Example 6 Evaluation and validation of the chimeric recombinant protein bHIV- 86 and bHIV-98 in a VTDAS® sandwich type test.
- EXAMPLE 7 Improvement of the Sensitivity of the Chimeric Recombinant Protein In order to further increase the recognition sensitivity of the anti-HIV antibodies of the recombinant protein obtained according to the invention, new epitopes characteristic of certain HIV subtypes can be added or a of the epitopes described can be duplicated in the sequence of the chimeric protein.
- Example 8 Addition of a hexalysin sequence to the recombinant protein to facilitate the coupling of an enzyme or biotin, in particular on the ⁇ -amino function of lysine.
- a sequence coding for six lysines can be fused 3 'to SEQ ID No. 2.
- the coupling of this recombinant protein to alkaline phosphatase in particular allows the use of the coupled protein in a sandwich format for revealing anti-HIV antibodies.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/526,765 US20060121049A1 (en) | 2002-09-17 | 2003-09-15 | Chimeric recombinant protein and in vitro diagnosis |
AU2003282159A AU2003282159A1 (en) | 2002-09-17 | 2003-09-15 | Chimeric recombinant protein and in vitro diagnosis of hiv |
EP03773778A EP1539963A2 (fr) | 2002-09-17 | 2003-09-15 | Proteine recombinante chimerique et diagnostic in vitro du hiv |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/11485 | 2002-09-17 | ||
FR0211485A FR2844519A1 (fr) | 2002-09-17 | 2002-09-17 | Proteine recombinante chimerique et diagnostic in vitro |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004027066A2 true WO2004027066A2 (fr) | 2004-04-01 |
WO2004027066A3 WO2004027066A3 (fr) | 2004-05-21 |
Family
ID=31897433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/002712 WO2004027066A2 (fr) | 2002-09-17 | 2003-09-15 | Protéine recombinante chimérique et diagnostic in vitro du hiv |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060121049A1 (fr) |
EP (1) | EP1539963A2 (fr) |
AU (1) | AU2003282159A1 (fr) |
FR (1) | FR2844519A1 (fr) |
WO (1) | WO2004027066A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007084021A2 (fr) * | 2006-01-17 | 2007-07-26 | Instituto De Medicina Molecular | Compositions et procédés de diagnostic de l'infection par vih-2 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3067814A1 (fr) * | 2017-06-20 | 2018-12-21 | Biomerieux | Procede d'application, sur un support solide, d'au moins un partenaire de liaison a une molecule |
AU2018304173A1 (en) | 2017-07-17 | 2020-01-30 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type III domains and methods of using the same |
CN112584860B (zh) | 2018-05-08 | 2024-04-05 | 凡恩世制药(北京)有限公司 | 抗dll3抗体及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0577894A1 (fr) * | 1992-06-17 | 1994-01-12 | Korea Green Cross Corporation | Conception, construction et expression de protéines chimériques pour le développement de vaccins et de réactifs diagnostiques |
WO1995033206A1 (fr) * | 1994-05-31 | 1995-12-07 | Abbott Laboratories | Detection de differents genotypes de vih utilisant un immunodosage modifie par un peptide synthetique |
WO1999009410A2 (fr) * | 1997-08-15 | 1999-02-25 | Abbott Laboratories | Titrage rapide pour la detection et la differenciation simultanees d'anticorps contre le vih |
DE10106295C1 (de) * | 2001-02-02 | 2002-08-22 | Gaifar German American Inst Fo | Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2172305A1 (fr) * | 1995-03-30 | 1996-10-01 | Muneo Aoyama | Peptide antigenique multiple, renfermant au moins deux peptides associes du virus de l'hepatite c |
-
2002
- 2002-09-17 FR FR0211485A patent/FR2844519A1/fr not_active Withdrawn
-
2003
- 2003-09-15 US US10/526,765 patent/US20060121049A1/en not_active Abandoned
- 2003-09-15 AU AU2003282159A patent/AU2003282159A1/en not_active Abandoned
- 2003-09-15 WO PCT/FR2003/002712 patent/WO2004027066A2/fr not_active Application Discontinuation
- 2003-09-15 EP EP03773778A patent/EP1539963A2/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0577894A1 (fr) * | 1992-06-17 | 1994-01-12 | Korea Green Cross Corporation | Conception, construction et expression de protéines chimériques pour le développement de vaccins et de réactifs diagnostiques |
WO1995033206A1 (fr) * | 1994-05-31 | 1995-12-07 | Abbott Laboratories | Detection de differents genotypes de vih utilisant un immunodosage modifie par un peptide synthetique |
WO1999009410A2 (fr) * | 1997-08-15 | 1999-02-25 | Abbott Laboratories | Titrage rapide pour la detection et la differenciation simultanees d'anticorps contre le vih |
DE10106295C1 (de) * | 2001-02-02 | 2002-08-22 | Gaifar German American Inst Fo | Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist |
Non-Patent Citations (3)
Title |
---|
HAN, B. ET AL.: "The use of a chimera HIV-1/HIV-2 envelope protein for immunodiagnosis of hiv infection : Its expression and purification in E. coli by use of translation initiation site within HIV-1 env gene" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 46, no. 3, octobre 1998 (1998-10), pages 607-617, XP008021044 ORLANDO, FL US cité dans la demande * |
SHIN S.Y. ET AL.: "The use of multiple antigenic peptide (MAP) in the immunodiagnosis of human deficiency virus infection" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 43, no. 4, novembre 1997 (1997-11), pages 713-721, XP008021043 ORLANDO, FL US cité dans la demande * |
VALLARI ET AL.: "Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 Group O and HIV-2" JOURNAL OF CLINICAL MICROBIOLOGY, vol. 36, no. 12, décembre 1998 (1998-12), pages 3657-3661, XP002252066 cité dans la demande * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007084021A2 (fr) * | 2006-01-17 | 2007-07-26 | Instituto De Medicina Molecular | Compositions et procédés de diagnostic de l'infection par vih-2 |
WO2007141650A2 (fr) * | 2006-01-17 | 2007-12-13 | Instituto De Medicina Molecular | Compositions et procédé destinés au diagnostic d'une infection hiv-2 |
WO2007084021A3 (fr) * | 2006-01-17 | 2008-02-14 | Inst De Medicina Molecular | Compositions et procédés de diagnostic de l'infection par vih-2 |
WO2007141650A3 (fr) * | 2006-01-17 | 2008-12-18 | Inst De Medicina Molecular | Compositions et procédé destinés au diagnostic d'une infection hiv-2 |
Also Published As
Publication number | Publication date |
---|---|
FR2844519A1 (fr) | 2004-03-19 |
EP1539963A2 (fr) | 2005-06-15 |
AU2003282159A1 (en) | 2004-04-08 |
WO2004027066A3 (fr) | 2004-05-21 |
US20060121049A1 (en) | 2006-06-08 |
AU2003282159A8 (en) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6215223B2 (ja) | マルチプレックス免疫スクリーニングアッセイ | |
CN101351550B (zh) | 具有卓越的伴侣和折叠活性的嵌合融合蛋白 | |
FR2838740A1 (fr) | Oligonucleotides issus des sequences codant pour la composante de surface des proteines d'enveloppe des ptlv et leurs utilisations | |
KR102076917B1 (ko) | 자가조립 나노 입자를 제조하기 위한 유전자 재조합 발현 벡터 시스템 및 이를 이용하는 방법 | |
CN111587291A (zh) | 用于快速有效捕获抗原的蛋白质 | |
JP2886861B2 (ja) | エイズ関連症の検出用合成抗原 | |
JP2008516210A (ja) | 治療、診断およびクロマトグラフィーに使用するためのタンパク質複合体 | |
FR2780069A1 (fr) | Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications | |
WO1999028439A2 (fr) | Erythrovirus et ses applications | |
CA2561163A1 (fr) | Antigene tat stabilise et ses applications pour la vaccination anti-vih | |
WO2004027066A2 (fr) | Protéine recombinante chimérique et diagnostic in vitro du hiv | |
EP1981904B1 (fr) | Domaine peptidique necessaire a l'interaction entre l'enveloppe d'un virus appartenant au groupe d'interference de herv-w et un recepteur hasct | |
EP0165830B1 (fr) | Anticorps monoclonaux anticytomégalovirus et procédés pour le diagnostic in vitro des infections par les cytomégalovirus humains et d'une protéine-kinase inductible par les cytomégalovirus et susceptible d'être reconnue par les susdits anticorps monoclonaux | |
WO2022167947A1 (fr) | Protéines de fusion ace2-fc recombinantes mutées pour le traitement des infections à covid-19 | |
FR2866025A1 (fr) | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras | |
EP0996731B1 (fr) | Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques | |
FR2721618A1 (fr) | Fragments d'acide nucléique et fragments peptidiques correspondants issus du génome du virus de l'arthrite et de l'encéphalite caprine (VAEC) et leurs applications. | |
EP0731168A1 (fr) | Virus MSRV-1 et agent pathogène et/ou infectant MSRV-2 associés à la polyarthrite rhumatoide | |
FR2808277A1 (fr) | Polypeptide du ttv, acide nucleique codant pour ce polypeptide et utilisations | |
WO2003055994A9 (fr) | Virus hxhv, matériel nucléique, matériel peptidique et utilisations | |
US20180221468A1 (en) | Haemophilus influenzae immunogen | |
FR2862974A1 (fr) | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras | |
EP1150693A1 (fr) | Compositions immunogenes utilisables comme vaccins | |
WO2005097180A1 (fr) | Antigene tat dimerique et ses applications pour la vaccination anti-vih. | |
JP2001033448A (ja) | 組み換え型ウイルス抗原の調製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003773778 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006121049 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10526765 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003773778 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10526765 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |